• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过定向进化发现具有潜在临床应用价值的类人 L-天冬酰胺酶。

Discovery of human-like L-asparaginases with potential clinical use by directed evolution.

机构信息

Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, United States of America.

The Jesse Brown VA Medical Center, Chicago, Illinois, United States of America.

出版信息

Sci Rep. 2017 Aug 31;7(1):10224. doi: 10.1038/s41598-017-10758-4.

DOI:10.1038/s41598-017-10758-4
PMID:28860480
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5579231/
Abstract

L-asparaginase is a chemotherapy drug used to treat acute lymphoblastic leukemia (ALL). The main prerequisite for clinical efficacy of L-asparaginases is micromolar K for asparagine to allow for complete depletion of this amino acid in the blood. Since currently approved L-asparaginases are of bacterial origin, immunogenicity is a challenge, which would be mitigated by a human enzyme. However, all human L-asparaginases have millimolar K for asparagine. We recently identified the low K guinea pig L-asparaginase (gpASNase1). Because gpASNase1 and human L-asparaginase 1 (hASNase1) share ~70% amino-acid identity, we decided to humanize gpASNase1 by generating chimeras with hASNase1 through DNA shuffling. To identify low K chimeras we developed a suitable bacterial selection system (E. coli strain BW5Δ). Transforming BW5Δ with the shuffling libraries allowed for the identification of several low K clones. To further humanize these clones, the C-terminal domain of gpASNase1 was replaced with that of hASNase1. Two of the identified clones, 63-h and 65-h, share respectively 85.7% and 87.1% identity with the hASNase1 but have a K similar to gpASNase1. These clones possess 100-140 fold enhanced catalytic efficiency compared to hASNase1. Notably, we also show that these highly human-like L-asparaginases maintain their in vitro ALL killing potential.

摘要

天冬酰胺酶是一种用于治疗急性淋巴细胞白血病 (ALL) 的化疗药物。天冬酰胺酶临床疗效的主要前提条件是对天冬酰胺的微摩尔 K 值,以允许血液中天冬酰胺完全耗尽。由于目前批准的天冬酰胺酶来源于细菌,因此免疫原性是一个挑战,如果是人类酶则可以减轻这种挑战。然而,所有人类天冬酰胺酶对天冬酰胺的 K 值都在毫摩尔范围内。我们最近鉴定了对 K 值要求低的豚鼠天冬酰胺酶(gpASNase1)。由于 gpASNase1 和人类天冬酰胺酶 1(hASNase1)共享约 70%的氨基酸同一性,因此我们决定通过 DNA 改组生成与 hASNase1 的嵌合体来对 gpASNase1 进行人源化。为了鉴定低 K 值嵌合体,我们开发了一个合适的细菌选择系统(E. coli 菌株 BW5Δ)。用改组文库转化 BW5Δ,可鉴定出几个低 K 值克隆。为了进一步人源化这些克隆,将 gpASNase1 的 C 末端结构域替换为 hASNase1 的 C 末端结构域。在鉴定的两个克隆 63-h 和 65-h 中,它们与 hASNase1 的同源性分别为 85.7%和 87.1%,但 K 值与 gpASNase1 相似。与 hASNase1 相比,这两个克隆的催化效率分别提高了 100-140 倍。值得注意的是,我们还表明这些高度类似人类的天冬酰胺酶保持了它们体外杀死 ALL 的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/14ba5598513a/41598_2017_10758_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/477163d8c621/41598_2017_10758_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/6802b76785a1/41598_2017_10758_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/c6d2c7053bfc/41598_2017_10758_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/c3e55ff1794a/41598_2017_10758_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/cfe182be3b30/41598_2017_10758_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/20543997b8d7/41598_2017_10758_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/14ba5598513a/41598_2017_10758_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/477163d8c621/41598_2017_10758_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/6802b76785a1/41598_2017_10758_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/c6d2c7053bfc/41598_2017_10758_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/c3e55ff1794a/41598_2017_10758_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/cfe182be3b30/41598_2017_10758_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/20543997b8d7/41598_2017_10758_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/5579231/14ba5598513a/41598_2017_10758_Fig7_HTML.jpg

相似文献

1
Discovery of human-like L-asparaginases with potential clinical use by directed evolution.通过定向进化发现具有潜在临床应用价值的类人 L-天冬酰胺酶。
Sci Rep. 2017 Aug 31;7(1):10224. doi: 10.1038/s41598-017-10758-4.
2
Identification and structural analysis of an L-asparaginase enzyme from guinea pig with putative tumor cell killing properties.从豚鼠中鉴定出具有假定肿瘤细胞杀伤特性的L-天冬酰胺酶并进行结构分析。
J Biol Chem. 2014 Nov 28;289(48):33175-86. doi: 10.1074/jbc.M114.609552. Epub 2014 Oct 15.
3
Human 60-kDa lysophospholipase contains an N-terminal L-asparaginase domain that is allosterically regulated by L-asparagine.人源 60kDa 溶血磷脂酶含有一个 N 端的 L-天冬酰胺酶结构域,该结构域受 L-天冬酰胺的别构调控。
J Biol Chem. 2014 May 9;289(19):12962-75. doi: 10.1074/jbc.M113.545038. Epub 2014 Mar 22.
4
Elucidation of the specific function of the conserved threonine triad responsible for human L-asparaginase autocleavage and substrate hydrolysis.阐明负责人类L-天冬酰胺酶自身切割和底物水解的保守苏氨酸三联体的具体功能。
J Mol Biol. 2014 Jun 26;426(13):2471-85. doi: 10.1016/j.jmb.2014.04.016. Epub 2014 Apr 22.
5
Structural and kinetic characterization of guinea pig L-asparaginase type III.豚鼠 L-天冬酰胺酶 III 的结构与动力学特征。
Biochemistry. 2014 Apr 15;53(14):2318-28. doi: 10.1021/bi401692v. Epub 2014 Apr 7.
6
Molecular dynamics simulations of human L-asparaginase1: Insights into structural determinants of enzymatic activity.人源 L-天冬酰胺酶 1 的分子动力学模拟:对酶活性结构决定因素的深入了解。
J Mol Graph Model. 2021 Dec;109:108007. doi: 10.1016/j.jmgm.2021.108007. Epub 2021 Aug 17.
7
Structures of apo and product-bound human L-asparaginase: insights into the mechanism of autoproteolysis and substrate hydrolysis.人源无酶蛋白和产物结合态天冬酰胺酶的结构:对自切割和底物水解机制的深入了解。
Biochemistry. 2012 Aug 28;51(34):6816-26. doi: 10.1021/bi300870g. Epub 2012 Aug 14.
8
Experimental Data in Support of a Direct Displacement Mechanism for Type I/II L-Asparaginases.支持I/II型L-天冬酰胺酶直接置换机制的实验数据。
J Biol Chem. 2016 Mar 4;291(10):5088-100. doi: 10.1074/jbc.M115.699884. Epub 2016 Jan 5.
9
The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity.人类天冬酰胺酶样蛋白1(hASRGL1)是一种具有β-天冬氨酰肽酶活性的Ntn水解酶。
Biochemistry. 2009 Nov 24;48(46):11026-31. doi: 10.1021/bi901397h.
10
[Bacterial recombinant L-asparaginases: properties, structure and anti-proliferative activity].[细菌重组L-天冬酰胺酶:特性、结构及抗增殖活性]
Biomed Khim. 2015 May-Jun;61(3):312-24. doi: 10.18097/PBMC20156103312.

引用本文的文献

1
Engineered L-asparaginase variants with enhanced therapeutic properties to improve treatment of childhood acute lymphatic leukemia.具有增强治疗特性的工程化L-天冬酰胺酶变体,用于改善儿童急性淋巴细胞白血病的治疗。
Cancer Gene Ther. 2025 Jul 30. doi: 10.1038/s41417-024-00865-6.
2
Toward Safer Biotherapeutics: Expression and Characterization of a Humanized Chimeric L-Asparaginase in .迈向更安全的生物治疗药物:人源化嵌合天冬酰胺酶在……中的表达与表征
Int J Mol Sci. 2025 Jul 18;26(14):6919. doi: 10.3390/ijms26146919.
3
Optimizing Gene Sources for L-asparaginase Production: A Comparative Review.

本文引用的文献

1
Fluorescence-Activated Cell Sorting of Human l-asparaginase Mutant Libraries for Detecting Enzyme Variants with Enhanced Activity.用于检测具有增强活性的酶变体的人L-天冬酰胺酶突变体文库的荧光激活细胞分选
ACS Chem Biol. 2016 Sep 16;11(9):2596-607. doi: 10.1021/acschembio.6b00283. Epub 2016 Aug 1.
2
Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.降低临床免疫原性的抗白血病L-天冬酰胺酶去免疫研究——一种计算机模拟方法
Pathol Oncol Res. 2015 Sep;21(4):909-20. doi: 10.1007/s12253-015-9912-0. Epub 2015 Mar 6.
3
Identification and structural analysis of an L-asparaginase enzyme from guinea pig with putative tumor cell killing properties.
优化L-天冬酰胺酶生产的基因来源:一项比较综述
Curr Microbiol. 2025 Jul 12;82(9):381. doi: 10.1007/s00284-025-04351-6.
4
Unveiling the Catalytic Mechanism and Conformational Dynamics of Guinea Pig l‑Asparaginase Type 1 for Leukemia Drug Design.揭示用于白血病药物设计的豚鼠I型天冬酰胺酶的催化机制和构象动力学。
ACS Catal. 2025 Apr 29;15(10):7919-7933. doi: 10.1021/acscatal.4c07791. eCollection 2025 May 16.
5
Asparaginase and isoaspartyl peptidase 1 RNA interference suppresses the growth of nasopharyngeal carcinoma cells.天冬酰胺酶和异天冬氨酰肽酶1 RNA干扰抑制鼻咽癌细胞的生长。
Discov Oncol. 2024 Nov 9;15(1):636. doi: 10.1007/s12672-024-01228-1.
6
Towards a dependable data set of structures for L-asparaginase research.致力于建立一个可靠的 L-天冬酰胺酶结构数据集。
Acta Crystallogr D Struct Biol. 2024 Jul 1;80(Pt 7):506-527. doi: 10.1107/S2059798324005461. Epub 2024 Jun 27.
7
Desirable L-asparaginases for treating cancer and current research trends.用于治疗癌症的理想L-天冬酰胺酶及当前研究趋势。
Front Microbiol. 2024 Mar 13;15:1269282. doi: 10.3389/fmicb.2024.1269282. eCollection 2024.
8
Engineering and Expression Strategies for Optimization of L-Asparaginase Development and Production.工程化与表达策略优化 L-天冬酰胺酶的开发与生产。
Int J Mol Sci. 2023 Oct 16;24(20):15220. doi: 10.3390/ijms242015220.
9
Enzyme Engineering Strategies for the Bioenhancement of L-Asparaginase Used as a Biopharmaceutical.酶工程策略用于增强作为生物制药的 L-天冬酰胺酶的生物利用度。
BioDrugs. 2023 Nov;37(6):793-811. doi: 10.1007/s40259-023-00622-5. Epub 2023 Sep 12.
10
In Silico Design of a Chimeric Humanized L-asparaginase.计算机设计嵌合型人源化 L-天冬酰胺酶
Int J Mol Sci. 2023 Apr 20;24(8):7550. doi: 10.3390/ijms24087550.
从豚鼠中鉴定出具有假定肿瘤细胞杀伤特性的L-天冬酰胺酶并进行结构分析。
J Biol Chem. 2014 Nov 28;289(48):33175-86. doi: 10.1074/jbc.M114.609552. Epub 2014 Oct 15.
4
Human 60-kDa lysophospholipase contains an N-terminal L-asparaginase domain that is allosterically regulated by L-asparagine.人源 60kDa 溶血磷脂酶含有一个 N 端的 L-天冬酰胺酶结构域,该结构域受 L-天冬酰胺的别构调控。
J Biol Chem. 2014 May 9;289(19):12962-75. doi: 10.1074/jbc.M113.545038. Epub 2014 Mar 22.
5
Library generation by gene shuffling.通过基因改组进行文库构建。
Curr Protoc Mol Biol. 2014 Jan 6;105:Unit 15.12.. doi: 10.1002/0471142727.mb1512s105.
6
High-throughput asparaginase activity assay in serum of children with leukemia.白血病患儿血清中天冬酰胺酶活性的高通量检测
Int J Clin Exp Med. 2013 Aug 1;6(7):478-87. Print 2013.
7
Directed enzyme evolution: beyond the low-hanging fruit.定向酶进化:超越低挂果实。
Curr Opin Struct Biol. 2012 Aug;22(4):406-12. doi: 10.1016/j.sbi.2012.03.010. Epub 2012 May 12.
8
Biocatalyst development by directed evolution.定向进化生物技术的生物催化剂开发。
Bioresour Technol. 2012 Jul;115:117-25. doi: 10.1016/j.biortech.2012.01.054. Epub 2012 Jan 21.
9
Engineering reduced-immunogenicity enzymes for amino acid depletion therapy in cancer.工程化降低免疫原性的酶用于癌症中的氨基酸耗竭疗法。
Methods Enzymol. 2012;502:291-319. doi: 10.1016/B978-0-12-416039-2.00015-X.
10
Strategy and success for the directed evolution of enzymes.酶定向进化的策略与成功。
Curr Opin Struct Biol. 2011 Aug;21(4):473-80. doi: 10.1016/j.sbi.2011.05.003. Epub 2011 Jun 16.